Table 2. Baseline characteristics of subjects at outcome, 12 months, and follow-up.
| Variable | Group A(interferon α+Ribavirin) n=32 | Group B (interferon α+Ribavirin+Rosuvastatin) n=33 | P-value Group A vs. Group B b | |||||
| Before treatment | After treatment | Follow-up | Before treatment | After treatment | Follow-up | After treatment | Follow-up | |
| AST (IU/ml) a | 146.1 ± 49.8 | 60.4 ± 38.0 (p < 0.01) | 78.2 ± 38.6 (p < 0.001) | 145.0 ± 46.8 | 38.5 ± 30.2 (p < 0.001) | 50.0 ± 34.1 (p < 0.001) | p < 0.001 | p < 0.001 |
| ALT (IU/ml) a | 160.0 ± 49.4 | 78.2 ± 40.2 (p < 0.001) | 84.6 ± 46.1 (p < 0.001) | 184.0 ± 49.2 | 57.8 ± 21.4 (p < 0.001) | 78.4 ± 28.8 (p < 0.001) | p < 0.001 | NS a |
| Total Cholesterol (mmol/L) | 5.11 ± 0.8 | 5.0 ± 0.9 (NS ) a | 5.0 ± 0.7 (NS ) a | 5.2 ± 0.7 | 4.6 ± 0.8 (p < 0.05) | 4.9 ± 0.9 (NS) a | NS a | NS a |
| HDL (mmol/L) a | 1.06 ± 0.8 | 1.07 ± 0.8 (NS) a | 1.04 ± 0.9 (NS) a | 1.08 ± 0.8 | 1.1 ± 0.2 (NS) a | 1.05 ± 0.7 (NS) a | NS a | NS a |
| LDL (mmol/L) a | 2.50 ± 0.73 | 2.51 ± 0.64 (NS) a | 2.5 ± 0.6 (NS) a | 2.6 ± 0.78 | 2.0 ± 0.8 (p < 0.05) | 2.2 ± 0.7 (p < 0.05) | p < 0.001 | NS a |
| Triglycerides (mmol/L) | 2.24 ± 0.71 | 2.41 ± 0.61 (NS) a | 2.8 ± 0.74 (NS) a | 2.2 ± 0.8 | 2.0 ± 0.4 (NS) a | 2.1 ± 0.6 (NS) a | p < 0.05 | p < 0.001 |
| Viremia (10(6) copies/ml) | 3.24 ± 1.22 | 1.44 ± 0.87 (p < 0.001) | 2.10 ± 0.98 (p < 0.001) | 3.44 ± 1.18 | 0.96 ± 0.70 (p < 0.001) | 1.33 ± 0.87 (p < 0.001) | p < 0.05 | p < 0.001 |
| CRP (mg/dl) a | 3.24 ± 0.56 | 7.04 ± 0.61 (p < 0.001) | 5.21 ± 0.44 (p < 0.001) | 3.43 ± 0.47 | 4.01 ± 0.61 (p < 0.001) | 1.96 ± 0.32 (p < 0.001) | p < 0.001 | NS a |
| Plasma Glucose (mmol/L) | 5.87 ± 0.67 | 6.18 ± 0.67 (NS) a | 5.91 ± 0.71 (NS) a | 5.96 ± 0.71 | 5.84 ± 0.56 (NS) a | 5.47 ± 0.51 (p < 0.05) | p < 0.05 | p < 0.05 |
| Insulin (mIU/ml) | 17.06 ± 5.0 | 19.6 ± 4.8 (p < 0.05) | 17.9 ± 6.2 (NS) a | 17.44 ± 5.1 | 16.9 ± 5.4 (NS) a | 16.0 ± 5.2 (NS) a | P < 0.05 | NS a |
| HOMA-IR | 3.14 ± 0.15 | 5.38 ± 0.14 (p < 0.001) | 4.02 ± 0.18 (p < 0.001) | 4.56 ± 0.16 | 4.38 ± 0.14 (p < 0.001) | 3.88 ± 0.12 (p < 0.001) | p < 0.001 | p < 0.001 |
a NS: not significant; AST: Aspartate Amino Transferase; ALT: Alanine Amino Transferase; HDL: High-Density Cholesterol Lipoprotein; LDL: Low-Density Cholesterol Lipoprotein; CRP: C-Reactiv
b There were no significant differences between groups at baseline.